| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2579697 | Thérapie | 2006 | 5 Pages |
Abstract
Beside vascular risk reduction, other antithrombotic agents are used as thrombolytics in the acute phase of stroke. The rt-PA (recombinant tissue plasminogen activator) administered in the first 3 hours dissolves the clot, preventing death and handicap due to ischemic brain lesion. But time window is short and rt-PA increase the risk of hemorragic stroke. Combination of new thrombolytic agents and new imaging technics should permit to rise the number of treated patients.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology, Toxicology and Pharmaceutics (General)
Authors
Philippa Lavallée,